To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.

The present phase I clinical trial was performed in order to investigate the ocular tolerance, safety and the ocular pharmacokinetics of a single administration of T1225 eye drops (0.5%, 1.0%, or 1.5%) in healthy volunteers.

Inclusion Criteria:

• Male or female aged from 18 to 45 years old;
• Written informed consent;
• Healthy volunteers (without any ocular symptom);
• Normal ocular examination in both eyes (corrected visual acuity (VA) >= 6/10 - slit lamp examination without clinical relevant abnormalities - tear break-up time (BUT) >= 10 seconds - lachrymal secretion in the Schirmer test >= 10 mm in 5 minutes - lissamine green test total score < 4).

Exclusion Criteria:

• Ocular trauma, infection or inflammation within the last 3 months;
• Conjunctival hyperaemia score >= 2, watering score >= 2, folliculo-papillary conjunctivitis score >= 2, number of fluorescein-stained punctuations >= 10;
• Blepharitis, conjunctivitis, uveitis;
• Ocular laser treatment within the last 3 months;
• Ocular surgery, including LASIK and PRK, within the last 12 months;
• Topical ocular treatment during the last month;
• Ocular antibiotics within the last 7 days;
• Medication during the study (except paracetamol and contraceptives).